Instant Notes: Immunology, Second Edition

Total Page:16

File Type:pdf, Size:1020Kb

Instant Notes: Immunology, Second Edition Immunology Second Edition The INSTANT NOTES series Series Editor: B.D. Hames School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK Animal Biology 2nd edition Biochemistry 2nd edition Bioinformatics Chemistry for Biologists 2nd edition Developmental Biology Ecology 2nd edition Immunology 2nd edition Genetics 2nd edition Microbiology 2nd edition Molecular Biology 2nd edition Neuroscience Plant Biology Chemistry series Consulting Editor: Howard Stanbury Analytical Chemistry Inorganic Chemistry 2nd edition Medicinal Chemistry Organic Chemistry 2nd edition Physical Chemistry Psychology series Sub-series Editor: Hugh Wagner Dept of Psychology, University of Central Lancashire, Preston, UK Psychology Cognitive Psychology Forthcoming title Physiological Psychology Immunology Second Edition P.M. Lydyard Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, University College London, London, UK A. Whelan Department of Immunology, Trinity College and St James’ Hospital, Dublin, Ireland and M.W. Fanger Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA © Garland Science/BIOS Scientific Publishers Limited, 2004 First published 2000 This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Second edition published 2004 All rights reserved. No part of this book may be reproduced or transmitted, in any form or by any means, without permission. A CIP catalogue record for this book is available from the British Library. ISBN 0-203-48828-8 Master e-book ISBN ISBN 0-203-59723-0 (Adobe eReader Format) ISBN 1 85996 039 1 (Print Edition) Garland Science/BIOS Scientific Publishers 4 Park Square, Milton Park, Abingdon, Oxon OX14 4RN, UK and 29 West 35th Street, New York, NY 10001–2299, USA Tel: (+1) 2122167800, Fax: (+1) 2125647854 World Wide Web home page: www.bios.co.uk Garland Science/BIOS Scientific Publishers is a member of the Taylor & Francis Group Distributed in the USA by Fulfilment Center Taylor & Francis 10650 Toebben Drive Independence, KY 41051, USA Toll Free Tel.: +1 800 634 7064; E-mail: [email protected] Distributed in Canada by Taylor & Francis 74 Rolark Drive Scarborough, Ontario M1R 4G2, Canada Toll Free Tel.: +1 877 226 2237; E-mail: [email protected] Distributed in the rest of the world by LibraryThomson of Publishing Congress Cataloging-in-PublicationServices Data Cheriton House North Way Andover, Hampshire SP10 5BE, UK Tel.:Patrick, +44 Graham (0)1264 L.332424; E-mail: [email protected] Production Editor: Andrew Watts Front cover: Confocal images of human dendritic cells stained by immunofluorescence for mannose receptors (green), HLA Class 1 (red) and colocalisation (yellow). Image kindly supplied by John Connolly, PhD. CONTENTS Abbreviations viii Preface x Key to cell symbols xi Section A – Overview of the immune system A1 The need 1 A2 External defenses 2 A3 Immune defense 5 A4 Antigens 9 A5 Hemopoiesis – development of blood cells 12 Section B – Cells and molecules of the innate immune system B1 Cells of the innate immune system 15 B2 Molecules of the innate immune system 23 B3 Recognition of microbes by the innate immune system 33 B4 Innate immunity and inflammation 36 Section C – The adaptive immune system C1 Lymphocytes 41 C2 Lymphoid organs and tissues 48 C3 Mucosa-associated lymphoid tissues 53 C4 Lymphocyte traffic and recirculation 56 C5 Adaptive immunity at birth 59 Section D – Antibodies D1 Antibody structure 61 D2 Antibody classes 65 D3 Generation of diversity 68 D4 Allotypes and idiotypes 78 D5 Monoclonal antibodies 80 D6 Antigen/antibody complexes (immune complexes) 83 D7 Immunoassay 87 D8 Antibody functions 93 Section E – The antibody response E1 The B cell receptor complex, co-receptors and signaling 99 E2 B cell activation 102 E3 The cellular basis of the antibody response 108 E4 Antibody responses in different tissues 112 Section F – The T cell response – cell-mediated immunity F1 The role of T cells in immune responses 115 F2 T cell recognition of antigen 117 F3 Shaping the T cell repertoire 124 F4 T cell activation 127 vi Contents F5 Clonal expansion and development of effector function 132 F6 Cell-mediated immunity in context 138 Section G – Regulation of the immune response G1 Overview 141 G2 Central and peripheral tolerance 145 G3 Acquired tolerance 149 G4 Regulation by antigen and antibody 152 G5 Genes, T helper cells, cytokines and the neuroendocrine system 155 Section H – Immunity to infection H1 The microbial cosmos 159 H2 Immunity to different organisms 162 H3 Pathogen defense strategies 167 Section I – Vaccination I1 Principles of vaccination 171 I2 Immunization 174 I3 Antigen preparations 177 I4 Vaccines to pathogens and tumors 181 Section J – Immunodeficiency – when the immune system fails J1 Deficiencies in the immune system 183 J2 Primary/congenital (inherited) immunodeficiency 185 J3 Secondary (acquired) immunodeficiency 189 J4 Diagnosis and treatment of immunodeficiency 192 Section K – Hypersensitivity – when the immune system overreacts K1 Definition and classification 197 K2 IgE-mediated (type I) hypersensitivity: allergy 199 K3 IgG and IgM-mediated (type II) hypersensitivity 204 K4 Immune-complex-mediated (type III) hypersensitivity 208 K5 Delayed (type IV) hypersensitivity 210 Section L – Autoimmunity and autoimmune diseases L1 The spectrum and prevalence of autoimmunity 215 L2 Factors contributing to the development of autoimmune disease 217 L3 Autoimmune diseases – mechanisms of development 222 L4 Disease pathogenesis – effector mechanisms 227 L5 Diagnosis and treatment of autoimmune disease 231 Section M – Transplantation M1 The transplantation problem 235 M2 Transplantation antigens 237 M3 Rejection mechanisms 240 M4 Prevention of graft rejection 243 Section N – Tumor immunology N1 Origin and host defense against tumors 249 Contents vii N2 Tumor antigens 250 N3 Immune responses to tumors 253 N4 Immunodiagnosis 256 N5 Cytokine and cellular immunotherapy of tumors 259 N6 Immunotherapy of tumors with antibodies 262 N7 Tumor vaccines 266 Section O – Gender and the immune system O1 Overview 269 O2 Immune cells and molecules associated with the reproductive tracts 271 O3 Functional effects of sex hormones on the immune system 279 Section P – Aging and the immune system (immunosenescence) P1 Overview 283 P2 Developmental changes in primary lymphoid tissue and lymphocytes with age 285 P3 Effects of aging on innate immunity 288 P4 The effects of aging on T cell immunity 290 P5 The effects of aging on humoral immunity 292 P6 Immunosenescence and morbidity, mortality and longevity 294 Further reading 297 Multiple Choice Questions 299 Appendix I – Selected CD molecules 315 Appendix II – The principal cytokines 317 Glossary 319 Index 325 ABBREVIATIONS 5HT 5′hydroxytryptamine HPA hypothalamus/pituitary/adrenal ADA adenosine deaminase HPV human papilloma virus ADCC antibody-dependent cell/cellular HSC hemopoietic stem cell cytotoxicity HTLV human T cell leukemia virus AFP alpha-fetoprotein IDC interdigitating cell AICD activation-induced cell death IEL intraepithelial lymphocyte AIDS acquired immune deficiency IF immunofluorescence syndrome IFN interferon AIHA autoimmune hemolytic anemia IL interleukin BALT bronchus-associated lymphoid ITAM immunoreceptor tyrosine-based tissue activation motif BCR B cell receptor ITIM immunoreceptor tyrosine-based CEA carcinoembryonic antigen inhibitory motif CGD chronic granulomatous disease ITP immune thrombocytopenic purpura CMV cytomegalovirus KAR killer activation receptor CRD carbohydrate recognition domain KIR killer inhibitory receptor CRH corticotrophin-releasing hormone LAK lymphokine-activated killer CRP C-reactive protein LCMV lymphocytic choriomeningitis virus CTL cytolytic/cytotoxic T lymphocyte LFA leukocyte function antigen CVID common variable LGL large granular lymphocyte immunodeficiency LH Langerhans cell DAF decay-accelerating factor LP late proliferative DAG diacyl glycerol LPS lipopolysaccharide DC dendritic cell LRR leucine-rich repeat DHEA dehydroepiandrosterone LS late secretory DHEAS dehydroepiandrosterone sulfate LSC lymphoid stem cells DTH delayed-type hypersensitivity MAC membrane attack complex EAE experimental allergic MALT mucosa-associated lymphoid tissue encephalomyelitis MBP mannose-binding protein EBV Epstein–Barr virus MCP membrane co-factor protein ELISA enzyme-linked immunosorbent M-CSF monocyte/macrophage colony- assay stimulating factor ER endoplasmic reticulum MDP muramyl dipeptide FDC follicular dendritic cell MHC major histocompatibility complex FRT female reproductive tract MØ macrophage GALT gut-associated lymphoid tissue MS multiple sclerosis GC germinal center MZ marginal zone G-CSF granulocyte colony-stimulating NALT nasal-associated lymphoid tissue factor NBT nitroblue tetrazolium test GI gastrointestinal NK natural killer GOD generation of diversity NO nitric oxide HAMA human anti-mouse antibody NSAID nonsteroidal anti-inflammatory HBV hepatitis B virus drugs HEV high endothelial venules PAF platelet-activating factor HHV8 human herpes virus 8 PALS periarteriolar lymphoid sheath HIV human immunodeficiency virus PCR polymerase chain reaction HLA human leukocyte antigen PMN polymorphonuclear cell Abbreviations ix PRR pattern recognition receptor SV splenic vein PS phosphatidyl serine TAA tumor-associated antigens
Recommended publications
  • Guidelines on the Diagnosis and Management of Pericardial
    European Heart Journal (2004) Ã, 1–28 ESC Guidelines Guidelines on the Diagnosis and Management of Pericardial Diseases Full Text The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology Task Force members, Bernhard Maisch, Chairperson* (Germany), Petar M. Seferovic (Serbia and Montenegro), Arsen D. Ristic (Serbia and Montenegro), Raimund Erbel (Germany), Reiner Rienmuller€ (Austria), Yehuda Adler (Israel), Witold Z. Tomkowski (Poland), Gaetano Thiene (Italy), Magdi H. Yacoub (UK) ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso Garcia (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), Joa~o Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway) Document Reviewers, Gianfranco Mazzotta, CPG Review Coordinator (Italy), Jean Acar (France), Eloisa Arbustini (Italy), Anton E. Becker (The Netherlands), Giacomo Chiaranda (Italy), Yonathan Hasin (Israel), Rolf Jenni (Switzerland), Werner Klein (Austria), Irene Lang (Austria), Thomas F. Luscher€ (Switzerland), Fausto J. Pinto (Portugal), Ralph Shabetai (USA), Maarten L. Simoons (The Netherlands), Jordi Soler Soler (Spain), David H. Spodick (USA) Table of contents Constrictive pericarditis . 9 Pericardial cysts . 13 Preamble . 2 Specific forms of pericarditis . 13 Introduction. 2 Viral pericarditis . 13 Aetiology and classification of pericardial disease. 2 Bacterial pericarditis . 14 Pericardial syndromes . ..................... 2 Tuberculous pericarditis . 14 Congenital defects of the pericardium . 2 Pericarditis in renal failure . 16 Acute pericarditis . 2 Autoreactive pericarditis and pericardial Chronic pericarditis . 6 involvement in systemic autoimmune Recurrent pericarditis . 6 diseases . 16 Pericardial effusion and cardiac tamponade .
    [Show full text]
  • Environments of Haematopoiesis and B-Lymphopoiesis in Foetal Liver K
    Environments of haematopoiesis and B-lymphopoiesis in foetal liver K. Kajikhina1, M. Tsuneto1,2, F. Melchers1 1Max Planck Fellow Research Group ABSTRACT potent myeloid/lymphoid progenitors on “Lymphocyte Development”, In human and murine embryonic de- (MPP), and their immediate progeny, Max Planck Institute for Infection velopment, haematopoiesis and B-lym- common myeloid progenitors (CMP) Biology, Berlin, Germany; phopoiesis show stepwise differentia- and common lymphoid progenitors 2Department of Stem Cell and Developmental Biology, Mie University tion from pluripotent haematopoietic (CLP) soon thereafter (10). The first Graduate School of Medicine, Tsu, Japan. stem cells and multipotent progenitors, T- or B-lymphoid lineage-directed pro- Katja Kajikhina over lineage-restricted lymphoid and genitors appear at E12.5-13.5, for T- Motokazu Tsuneto, PhD myeloid progenitors to B-lineage com- lymphocytes in the developing thymus Fritz Melchers, PhD mitted precursors and finally differenti- (11), for B-lymphocytes in foetal liver Please address correspondence to: ated pro/preB cells. This wave of dif- (12). Time in development, therefore, Fritz Melchers, ferentiation is spatially and temporally separates and orders these different Max Planck Fellow Research Group organised by the surrounding, mostly developmental haematopoietic stages. on “Lymphocyte Development”, non-haematopoietic cell niches. We re- Three-dimensional imaging of progen- Max Planck Institute for Infection Biology, view here recent developments and our itors and precursors indicates that stem Chariteplatz 1, current contributions on the research D-10117 Berlin, Germany. cells are mainly found inside the em- E-mail: [email protected] on blood cell development. bryonic blood vessel, and are attracted Received and accepted on August 28, 2015.
    [Show full text]
  • M.Tech. BT ( R14 Regulations)
    M.Tech. BT ( R14 Regulations) CMR COLLEGE OF ENGINEERING & TECHNOLOGY (An Autonomous Institution) ACADEMIC REGULATIONS FOR M. TECH. (REGULAR) DEGREE COURSE Applicable for the students of M. Tech. (Regular) Course from the Academic Year 2014-15 and onwards The M. Tech. degree shall be conferred on candidates who are admitted to the program and who fulfil all the requirements for the award of the degree. 1.0 Eligibility for Admissions Admission to the above program shall be made subject to eligibility, qualification and specialization as prescribed by the State Government from time to time. 2.0 Award of M. Tech. degree 2.1 A student shall be declared eligible for the award of the M. Tech. Degree, if he pursues a course of study in not less than two and not more than four academic years. 2.2 A student, who fails to fulfill all the academic requirements for the award of the degree within four academic years from the year of his admission, shall forfeit his seat in M. Tech. course. 2.3 The student shall register for all 88 credits and secure all the 88 credits. 2.4 The minimum instruction days in each semester are 90. 2.5 The medium of instruction and examination shall be English. 3.0 A. Courses of Study The following specializations are offered at present for the M. Tech. course of study. 1. Bio-Technology 2. Embedded Systems 3. Power Electronics 4. Structural Engineering 5. Computer Science & Engineering 6. Machine Design and any other course as approved by the College/ University/AICTE from time to time.
    [Show full text]
  • An Essential Role of UBXN3B in B Lymphopoiesis Tingting Geng Et Al. This File Contains 9 Supplemental Figures and Legends
    An Essential Role of UBXN3B in B Lymphopoiesis Tingting Geng et al. This file contains 9 supplemental figures and legends. a Viral load (relative) load Viral Serum TNF-α b +/+ Serum IL-6 Ubxn3b Ubxn3b-/- Ubxn3b+/+ 100 100 ** Ubxn3b-/- ** 10 10 IL-6 IL-6 (pg/ml) GM-CSF (pg/ml) GM-CSF 1 1 0 3 8 14 35 0 3 8 14 35 Time post infection (Days) Time post infection (Days) Serum IL-10 Serum CXCL10 Ubxn3b+/+ Ubxn3b-/- 10000 1000 +/+ -/- * Ubxn3b Ubxn3b 1000 100 IFN-γ (pg/ml) CXCL10 (pg/ml) CXCL10 100 10 0 3 8 14 35 0 3 8 14 35 Time post infection (Days) Time post infection (Days) IL-1β IL-1β (pg/ml) Supplemental Fig.s1 UBXN3B is essential for controlling SARS-CoV-2 pathogenesis. Sex- and-age matched littermates were administered 2x105 plaque forming units (PFU) of SARS-CoV-2 intranasally. a) Quantitative RT-PCR (qPCR) quantification of SARS-CoV-2 loads in the lung at days 3 and 10 post infection (p.i). Each symbol= one mouse, the small horizontal line: the median of the result. *, p<0.05; **, p<0.01, ***, p<0.001 (non-parametric Mann-Whitney test) between Ubxn3b+/+ and Ubxn3b-/- littermates at each time point. Ubxn3b+/+ Ubxn3b-/- Live Live 78.0 83.6 CD45+ CD45+ UV UV CD45 94.1 CD45 90.9 FSC-A FSC-A FSC-A FSC-A Mac Mac 23.0 38.1 MHC II MHC II CD11b Eso CD11b Eso 5.81 7.44 CD19, MHCII subset F4_80, CD11b subset CD19, MHCII subset F4_80, CD11b subset Myeloid panel Myeloid 70.1 65.6 94.2 51.1 CD19 F4/80 CD19 F4/80 Neu DC Neu DC 4.87 1.02 16.2 2.24 CD11b, Ly-6G subset CD11b, Ly-6G subset 94.9 83.3 Ly-6G Ly-6G MHC II MHC II CD11b CD11c CD11b CD11c Live Live 82.3 76.5 CD45+ CD45+ 91.1 91.3 UV UV CD45 CD45 FSC-A FSC-A FSC-A FSC-A Q1 Q2 Q1 Q2 Q1 Q2 Q1 Q2 Lymphoid panel Lymphoid 20.1 0.29 54.1 1.17 4.27 0.060 39.2 2.55 CD4 CD4 CD19 CD19 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 47.0 32.6 7.21 37.5 67.7 28.0 7.27 51.0 CD3 CD8 CD3 CD8 Supplemental Fig.s2 Dysregulated immune compartmentalization in Ubxn3b-/- lung.
    [Show full text]
  • NLRP3 Inflammasome Cutting Edge
    Cutting Edge: Nitric Oxide Inhibits the NLRP3 Inflammasome Eduardo Hernandez-Cuellar, Kohsuke Tsuchiya, Hideki Hara, Rendong Fang, Shunsuke Sakai, Ikuo Kawamura, This information is current as Shizuo Akira and Masao Mitsuyama of September 25, 2021. J Immunol published online 24 October 2012 http://www.jimmunol.org/content/early/2012/10/24/jimmun ol.1202479 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/10/24/jimmunol.120247 Material 9.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 24, 2012, doi:10.4049/jimmunol.1202479 Cutting Edge: Nitric Oxide Inhibits the NLRP3 Inflammasome Eduardo Hernandez-Cuellar,*,† Kohsuke Tsuchiya,* Hideki Hara,* Rendong Fang,* Shunsuke Sakai,* Ikuo Kawamura,* Shizuo Akira,† and Masao Mitsuyama* Although the NLRP3 inflammasome plays a pivotal role in that NLRP3 inflammasome contributes to host defense against host defense, its uncontrolled activation is associated with microbialpathogens,excessiveactivationduetomutationsinthe inflammatory disorders, suggesting that regulation of the NLRP3 gene has been associated with a spectrum of autoin- inflammasome is important to prevent detrimental effects.
    [Show full text]
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • Eosinophil-Derived Neurotoxin (EDN/Rnase 2) and the Mouse Eosinophil-Associated Rnases (Mears): Expanding Roles in Promoting Host Defense
    Int. J. Mol. Sci. 2015, 16, 15442-15455; doi:10.3390/ijms160715442 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Eosinophil-Derived Neurotoxin (EDN/RNase 2) and the Mouse Eosinophil-Associated RNases (mEars): Expanding Roles in Promoting Host Defense Helene F. Rosenberg Inflammation Immunobiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; E-Mail: [email protected]; Tel.: +1-301-402-1545; Fax: +1-301-480-8384 Academic Editor: Ester Boix Received: 18 May 2015 / Accepted: 30 June 2015 / Published: 8 July 2015 Abstract: The eosinophil-derived neurotoxin (EDN/RNase2) and its divergent orthologs, the mouse eosinophil-associated RNases (mEars), are prominent secretory proteins of eosinophilic leukocytes and are all members of the larger family of RNase A-type ribonucleases. While EDN has broad antiviral activity, targeting RNA viruses via mechanisms that may require enzymatic activity, more recent studies have elucidated how these RNases may generate host defense via roles in promoting leukocyte activation, maturation, and chemotaxis. This review provides an update on recent discoveries, and highlights the versatility of this family in promoting innate immunity. Keywords: inflammation; leukocyte; evolution; chemoattractant 1. Introduction The eosinophil-derived neurotoxin (EDN/RNase 2) is one of the four major secretory proteins found in the specific granules of the human eosinophilic leukocyte (Figure 1). EDN, and its more highly charged and cytotoxic paralog, the eosinophil cationic protein (ECP/RNase 3) are released from eosinophil granules when these cells are activated by cytokines and other proinflammatory mediators [1,2].
    [Show full text]
  • The Case for Lupus Nephritis
    Journal of Clinical Medicine Review Expanding the Role of Complement Therapies: The Case for Lupus Nephritis Nicholas L. Li * , Daniel J. Birmingham and Brad H. Rovin Department of Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH 43210, USA; [email protected] (D.J.B.); [email protected] (B.H.R.) * Correspondence: [email protected]; Tel.: +1-614-293-4997; Fax: +1-614-293-3073 Abstract: The complement system is an innate immune surveillance network that provides defense against microorganisms and clearance of immune complexes and cellular debris and bridges innate and adaptive immunity. In the context of autoimmune disease, activation and dysregulation of complement can lead to uncontrolled inflammation and organ damage, especially to the kidney. Systemic lupus erythematosus (SLE) is characterized by loss of tolerance, autoantibody production, and immune complex deposition in tissues including the kidney, with inflammatory consequences. Effective clearance of immune complexes and cellular waste by early complement components protects against the development of lupus nephritis, while uncontrolled activation of complement, especially the alternative pathway, promotes kidney damage in SLE. Therefore, complement plays a dual role in the pathogenesis of lupus nephritis. Improved understanding of the contribution of the various complement pathways to the development of kidney disease in SLE has created an opportunity to target the complement system with novel therapies to improve outcomes in lupus nephritis. In this review, we explore the interactions between complement and the kidney in SLE and their implications for the treatment of lupus nephritis. Keywords: lupus nephritis; complement; systemic lupus erythematosus; glomerulonephritis Citation: Li, N.L.; Birmingham, D.J.; Rovin, B.H.
    [Show full text]
  • Cells, Tissues and Organs of the Immune System
    Immune Cells and Organs Bonnie Hylander, Ph.D. Aug 29, 2014 Dept of Immunology [email protected] Immune system Purpose/function? • First line of defense= epithelial integrity= skin, mucosal surfaces • Defense against pathogens – Inside cells= kill the infected cell (Viruses) – Systemic= kill- Bacteria, Fungi, Parasites • Two phases of response – Handle the acute infection, keep it from spreading – Prevent future infections We didn’t know…. • What triggers innate immunity- • What mediates communication between innate and adaptive immunity- Bruce A. Beutler Jules A. Hoffmann Ralph M. Steinman Jules A. Hoffmann Bruce A. Beutler Ralph M. Steinman 1996 (fruit flies) 1998 (mice) 1973 Discovered receptor proteins that can Discovered dendritic recognize bacteria and other microorganisms cells “the conductors of as they enter the body, and activate the first the immune system”. line of defense in the immune system, known DC’s activate T-cells as innate immunity. The Immune System “Although the lymphoid system consists of various separate tissues and organs, it functions as a single entity. This is mainly because its principal cellular constituents, lymphocytes, are intrinsically mobile and continuously recirculate in large number between the blood and the lymph by way of the secondary lymphoid tissues… where antigens and antigen-presenting cells are selectively localized.” -Masayuki, Nat Rev Immuno. May 2004 Not all who wander are lost….. Tolkien Lord of the Rings …..some are searching Overview of the Immune System Immune System • Cells – Innate response- several cell types – Adaptive (specific) response- lymphocytes • Organs – Primary where lymphocytes develop/mature – Secondary where mature lymphocytes and antigen presenting cells interact to initiate a specific immune response • Circulatory system- blood • Lymphatic system- lymph Cells= Leukocytes= white blood cells Plasma- with anticoagulant Granulocytes Serum- after coagulation 1.
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts Via Formyl-Peptide Receptors
    Original Paper Int Arch Allergy Immunol 2006;140:103–112 Received: January 3, 2005 Accepted after revision: December 19, 2005 DOI: 10.1159/000092305 Published online: March 24, 2006 Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors a a b G. Sandra Tjabringa Dennis K. Ninaber Jan Wouter Drijfhout a a Klaus F. Rabe Pieter S. Hiemstra a b Departments of Pulmonology, and Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden , The Netherlands Key Words ting using antibodies directed against phosphorylated Eosinophils Neutrophils Chemotaxis Antimicrobial ERK1/2. Results: Our results show that LL-37 chemoat- peptides Innate immunity Lung infl ammation tracts both eosinophils and neutrophils. The FPR antag- onistic peptide tBoc-MLP inhibited LL-37-induced che- motaxis. Whereas the FPR agonist fMLP activated ERK1/2 Abstract in neutrophils, LL-37 did not, indicating that fMLP and Background: Infl ammatory lung diseases such as asth- LL-37 deliver different signals through FPRs. Conclu- ma and chronic obstructive pulmonary disease (COPD) sions: LL-37 displays chemotactic activity for eosinophils are characterized by the presence of eosinophils and and neutrophils, and this activity is mediated via an FPR. neutrophils. However, the mechanisms that mediate the These results suggest that LL-37 may play a role in in- infl ux of these cells are incompletely understood. Neu- fl ammatory lung diseases such as asthma and COPD. trophil products, including neutrophil elastase and anti- Copyright © 2006 S. Karger AG, Basel microbial peptides such as neutrophil defensins and LL- 37, have been demonstrated to display chemotactic activity towards cells from both innate and adaptive im- Introduction munity.
    [Show full text]
  • Immunosenescence: a Key Player in Cancer Development Jingyao Lian1,2†, Ying Yue1,2,3†, Weina Yu1,2† and Yi Zhang1,2*
    Lian et al. J Hematol Oncol (2020) 13:151 https://doi.org/10.1186/s13045-020-00986-z REVIEW Open Access Immunosenescence: a key player in cancer development Jingyao Lian1,2†, Ying Yue1,2,3†, Weina Yu1,2† and Yi Zhang1,2* Abstract Immunosenescence is a process of immune dysfunction that occurs with age and includes remodeling of lymphoid organs, leading to changes in the immune function of the elderly, which is closely related to the development of infections, autoimmune diseases, and malignant tumors. T cell–output decline is an important feature of immunose- nescence as well as the production of senescence-associated secretory phenotype, increased glycolysis, and reactive oxygen species. Senescent T cells exhibit abnormal phenotypes, including downregulation of CD27, CD28, and upreg- ulation of CD57, killer cell lectin-like receptor subfamily G, Tim-3, Tight, and cytotoxic T-lymphocyte-associated protein 4, which are tightly related to malignant tumors. The role of immunosenescence in tumors is sophisticated: the many factors involved include cAMP, glucose competition, and oncogenic stress in the tumor microenvironment, which can induce the senescence of T cells, macrophages, natural killer cells, and dendritic cells. Accordingly, these senescent immune cells could also afect tumor progression. In addition, the efect of immunosenescence on the response to immune checkpoint blocking antibody therapy so far is ambiguous due to the low participation of elderly cancer patients in clinical trials. Furthermore, many other senescence-related interventions could be possible with genetic and pharmacological methods, including mTOR inhibition, interleukin-7 recombination, and NAD + activation. Overall, this review aims to highlight the characteristics of immunosenescence and its impact on malignant tumors and immunotherapy, especially the future directions of tumor treatment through senescence-focused strategies.
    [Show full text]